The Heart Institute, University of São Paulo is one of the clinical institutes of the central University's teaching hospital and recognized as one of the world's academic and clinical excellence centers in cardiology, cardiovascular medicine and cardiovascular surgery.

During the past decade, Incor - Heart Institute - University of Sao Paulo conducted 82 clinical trials. In the 10-year time frame, 82 clinical trials started and 12 clinical trials were completed, i.e. on average, 14.6% percent of trials that started reached the finish line to date. In the past 5 years, 33 clinical trials started and 8 clinical trials were completed. i.e. 24.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Incor - Heart Institute - University of Sao Paulo" #1 sponsor was "University of Sao Paulo General Hospital" with 39 trials, followed by "University of Sao Paulo" with 17 trials sponsored, "InCor Heart Institute" with 8 trials sponsored, "Instituto do Coracao" with 8 trials sponsored and "Boehringer Ingelheim" with 8 trials sponsored. Other sponsors include 42 different institutions and companies that sponsored additional 39 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Incor - Heart Institute - University of Sao Paulo" #1 collaborator was "Fundação de Amparo à Pesquisa do Estado de São Paulo" with 18 trials as a collaborator, "Conselho Nacional de Desenvolvimento Científico e Tecnológico" with 5 trials as a collaborator, "Eli Lilly and Company" with 4 trials as a collaborator, "InCor Heart Institute" with 4 trials as a collaborator and "Ministry of Health, Brazil" with 4 trials as a collaborator. Other collaborators include 54 different institutions and companies that were collaborators in the rest 51 trials.

According to Clinical.Site data, the most researched conditions in "Incor - Heart Institute - University of Sao Paulo" are "Heart Failure" (15 trials), "Coronary Artery Disease" (12 trials), "Cardiac Surgery" (5 trials), "Pulmonary Arterial Hypertension" (5 trials) and "C.Surgical Procedure; Cardiac" (4 trials). Many other conditions were trialed in "Incor - Heart Institute - University of Sao Paulo" in a lesser frequency.

Most popular intervention types in "Incor - Heart Institute - University of Sao Paulo" are "Drug" (54 trials), "Device" (22 trials), "Other" (21 trials), "Procedure" (14 trials) and "Diagnostic Test" (7 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (17 trials), "Empagliflozin" (3 trials), "Enoxaparin" (2 trials), "Exercise training" (2 trials) and "Placebo Oral Tablet" (2 trials). Other intervention names were less common.

The vast majority of trials in "Incor - Heart Institute - University of Sao Paulo" are 120 trials for "All" genders, 3 trials for "Male" genders and 2 trials for "Female" genders.

Currently, there are 32 active trials in "Incor - Heart Institute - University of Sao Paulo". 2 are not yet recruiting, 20 are recruiting, 8 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 49 completed trials in Incor - Heart Institute - University of Sao Paulo, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Incor - Heart Institute - University of Sao Paulo, 1 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 35 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 20 trials, and there were also 43 trials that are defined as “Not Applicable".